US Patent 8853161 Glycopegylation methods and proteins/peptides produced by the methods

Patent 8853161 was granted and assigned to Novo Nordisk on October, 2014 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Current Assignee

Novo Nordisk

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

88531610

Patent Inventor Names

Robert J. Bayer0

Xi Chen0

Caryn Bowe0

David A. Zopf0

David James Hakes0

Shawn DeFrees0

Date of Patent

October 7, 2014

Patent Application Number

132465120

Date Filed

September 27, 2011

Patent Citations Received

‌

US Patent 12110338 Site-specific antibody-drug conjugation through glycoengineering

Patent Primary Examiner

‌

Thomas Heard

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 8853161 Glycopegylation methods and proteins/peptides produced by the methods

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API